XCUR logo

Exicure Inc. (XCUR)

$1.08

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on XCUR

Market cap

$7069675

EPS

-1.34

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

3.828578

Price on XCUR

Previous close

$1.07

Today's open

$1.05

Day's range

$1.01 - $1.08

52 week range

$0.78 - $9.48

Profile about XCUR

CEO

Jungsoo Kim

Employees

8

Headquarters

Wilmington, DE

Exchange

NASDAQ Capital Market

Shares outstanding

6545995

Issue type

Common Stock

XCUR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on XCUR

Exicure Announces Filing of Notification of Late Filing on Form 12b-25

WILMINGTON, Del., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it filed a Notification of Late Filing on Form 12b-25 with the Securities and Exchange Commission (the “SEC”) with respect to its Quarterly Report on Form 10-Q for the three months ended September 30, 2026 (the “Form 10-Q”).

news source

GlobeNewsWire • Nov 16, 2026

news preview

Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet

Exicure Inc. (NASDAQ:XCUR) agreed to sell its GPC-100 program assets to South Korea-based GPCRT Inc. for an aggregate cash price of 6.5 billion South Korean won (approximately $4.8 million).

news source

Benzinga • Nov 11, 2026

news preview

Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion

WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (“GPCR USA”), entered into an Intellectual Property, Asset and License Assignment Agreement (the “Agreement”) with GPCRT Inc. (“GPCRT”), a company organized under the laws of the Republic of Korea, under which GPCRT has agreed to acquire the Company's GPC-100 (burixafor) program assets for an aggregate cash purchase price of KRW 6.5 billion (approximately US$4.8 million).

news source

GlobeNewsWire • Nov 10, 2026

news preview

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1).

news source

GlobeNewsWire • Sep 16, 2026

news preview

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties' License and Collaboration Agreement.

news source

GlobeNewsWire • Aug 3, 2026

news preview

Exicure Announces Board and Committee Changes

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026.

news source

GlobeNewsWire • Jun 30, 2026

news preview

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 5, 2026 indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity.

news source

GlobeNewsWire • Jun 10, 2026

news preview

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.

news source

GlobeNewsWire • Jun 1, 2026

news preview

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.

news source

GlobeNewsWire • Apr 22, 2026

news preview

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice: TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF EXICURE, INC.

news source

GlobeNewsWire • Apr 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Exicure Inc.

Open an M1 investment account to buy and sell Exicure Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in XCUR on M1